SHPH NASDAQ
Shuttle Pharmaceuticals Holdings, Inc.
1W: +6.1%
1M: +26.8%
3M: +87.4%
YTD: +187.8%
1Y: +67.0%
3Y: -94.7%
$5.21
+0.17 (+3.27%)
Pre-Market: $5.03 (-0.18, -3.55%)
Weekly Expected Move ±16.0%
$3
$4
$5
$6
$7
Credit Risk of going bust: higher than 94% of companies Debt: 0.8% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the riskiest tenth, about 1 in 20 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.02 (down 99.7%), Shuttle Pharmaceuticals Holdings, Inc. would be worth roughly what it owes.
Total debt $195K against a stock market value of $24.8M.
Distance to default 0.85 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $98K (short-term plus half of long-term), stock volatility 260.6%; Altman Z -0.82. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.02 (down 99.7%), Shuttle Pharmaceuticals Holdings, Inc. would be worth roughly what it owes.
Total debt $195K against a stock market value of $24.8M.
Distance to default 0.85 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $98K (short-term plus half of long-term), stock volatility 260.6%; Altman Z -0.82. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
31 relationships31
As Filer
counterparties named
0
As Counterparty
mentioned by others
7
Rel. Types
2022-09-19
Earliest Filing
2025-12-29
Latest Filing
partner: 7
target: 6
investor: 5
supplier: 4
customer: 4
acquirer: 3
licensee: 2
Counterparties (Filed by SHPH)
31 relationshipsCompanies named in SHPH's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Shuttle Pharmaceuticals Holdings, Inc. | SHPH | acquirer | Parent company issuing stock as part of purchase price | 2025-12-29 | View |
| 1563868 B.C. Ltd. | — | acquirer | Purchaser acquiring Transferred Assets | 2025-12-29 | View |
| 1542770 BC Ltd. | — | target | Seller of Transferred Assets | 2025-12-29 | View |
| Theradex Systems, Inc. | — | partner | Creditor in settlement agreement accepting partial payment in full | 2025-11-21 | View |
| Shuttle Pharmaceuticals Holding, Inc. | SHPH | partner | Debtor in settlement agreement making partial payment to resolve debt | 2025-11-21 | View |
| Molecule | — | target | Canadian limited liability company being acquired in asset purchase transaction | 2025-10-21 | View |
| Shuttle Pharmaceuticals Holdings, Inc. | SHPH | acquirer | Delaware corporation acquiring substantially all assets and liabilities of Molecule | 2025-10-21 | View |
| IR Agency LLC | — | supplier | Consulting firm providing marketing and advertising services to Shuttle Pharmaceuticals Holdings Inc. | 2025-09-22 | View |
| Shuttle Pharmaceuticals Holdings Inc | SHPH | customer | Client engaging IR Agency LLC for marketing and advertising services. | 2025-09-22 | View |
| IR Agency LLC | — | supplier | Consulting firm providing marketing and advertising services to Shuttle Pharmaceuticals Holdings Inc. | 2025-04-04 | View |
| Shuttle Pharmaceuticals Holdings Inc | SHPH | customer | Client engaging IR Agency LLC for marketing and advertising services. | 2025-04-04 | View |
| WestPark Capital, Inc. | — | partner | Acting as representative to the several underwriters for the purchase of securities. | 2025-03-13 | View |
| Shuttle Pharmaceuticals Holdings, Inc. | SHPH | target | Company issuing warrants and notes and entering into amendment agreement | 2025-02-27 | View |
| Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B | — | investor | Holder of warrants and notes entering into amendment agreement | 2025-02-27 | View |
| Theradex Systems, Inc. | — | partner | Provider of services for Phase 2 IPdR Glioblastoma study | 2025-01-28 | View |
| Shuttle Pharmaceuticals, Inc. | SHPH | customer | Sponsor of Phase 2 IPdR Glioblastoma study | 2025-01-28 | View |
| Theradex Oncology | — | supplier | Provider of clinical trial services including study management, monitoring, and data analysis for a Phase 2 glioblastoma | 2024-08-14 | View |
| Shuttle Pharmaceuticals, Inc. | SHPH | customer | Sponsor of the Phase 2 clinical study receiving services from Theradex Oncology. | 2024-08-14 | View |
| Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B | — | investor | Holder of warrants and senior secured convertible notes; party to amendment regarding default waiver and collateral. | 2024-08-07 | View |
| Shuttle Pharmaceuticals Holdings, Inc. | SHPH | target | Issuer of warrants and notes; borrower in the transaction documents. | 2024-08-07 | View |
| SRO, LLC | — | investor | Buyer committing to purchase 50% of the Offering proceeds via a rights offering. | 2024-02-13 | View |
| Georgetown University | — | licensee | University granting exclusive license for predictive biomarkers invention | 2023-10-30 | View |
| Shuttle Pharmaceuticals Holdings, Inc. | SHPH | licensee | Company receiving exclusive license to develop and commercialize patented technology | 2023-10-30 | View |
| Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B | — | investor | Holder of Senior Secured Convertible Note and Warrant; exercising option to purchase additional notes and warrants. | 2023-06-05 | View |
| Shuttle Pharmaceuticals Holdings, Inc. | SHPH | target | Issuer of the Senior Secured Convertible Note and Warrant; releasing cash collateral. | 2023-06-05 | View |
| Shuttle Pharmaceuticals, Inc. | SHPH | partner | Guarantor of the obligations under the Securities Purchase Agreement and Note. | 2023-06-05 | View |
| Shuttle Pharmaceuticals Holdings, Inc. | SHPH | target | Issuer of warrants and notes seeking to amend terms | 2023-05-11 | View |
| Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B | — | investor | Holder of warrants and senior secured convertible notes | 2023-05-11 | View |
| Shuttle Pharmaceuticals Holdings, Inc. | SHPH | partner | Client seeking cGMP manufacturing of IPdR | 2022-09-19 | View |
| TCG GreenChem, Inc. | — | supplier | Contract Innovator Organization providing process R&D and cGMP manufacturing | 2022-09-19 | View |
| TCG Lifesciences Pvt Ltd | — | partner | Parent company of TCG GreenChem, Inc. | 2022-09-19 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-22 | Accountant Change; Exhibits | View | |
| 2026-09-24 | Exhibits | View | |
| 2026-09-16 | Unregistered Equity Sales; Exhibits | View | |
| 2026-09-11 | Shareholder Vote; Exhibits | View | |
| 2026-09-02 | Other Events; Exhibits | View | |
| 2026-09-01 | Material Agreement; Exhibits | Agreement | View |
| 2026-08-28 | Delisting Notice; Regulation FD; Exhibits | View | |
| 2026-08-17 | Acquisition/Disposition; Exhibits | Acquisition | View |
| 2026-07-01 | Regulation FD; Other Events; Exhibits | View | |
| 2026-06-11 | Bylaws Amendment; Exhibits | View | |
| 2026-05-27 | Shareholder Vote | View | |
| 2026-05-07 | Material Agreement; Acquisition/Disposition; Unregistered Equity Sales; Officer/Director Change; Byl | Agreement Acquisition | View |
| 2026-05-01 | Material Agreement; Unregistered Equity Sales; Regulation FD; Exhibits | Agreement | View |
| 2026-03-10 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibit | Agreement | View |
| 2026-02-17 | Results of Operations and Financial Condition | View | |
| 2026-02-02 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2026-01-12 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-12-29 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Financial Stateme | Agreement | View |
| 2025-11-28 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-11-26 | Entry into Material Definitive Agreement; Completion of Acquisition or Disposition of Assets; Unregi | Agreement Acquisition | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR